Digital Content 
NEWS #PharmaBuzz
20 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251015179453/en/Exelixis-Announces-Detailed-Results-from-Phase-3-STELLAR-303-Pivotal-Trial-Evaluating-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-in-Metastatic-Colorectal-Cancer-Presented-at-ESMO-2025-and-Published-in-The-Lancet
06 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html
22 Jun 2024
// PRESS RELEASE
https://www.takeda.com/newsroom/newsreleases/2024/approval-from-european-commission-for-fruzaqla/
20 Jan 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html
14 Dec 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html
21 Sep 2022
// BUSINESSWIRE
Share 